Food Study of Fexofenadine Tablets 180 mg and Allegra® Tablets 180 mg
Status:
Completed
Trial end date:
2003-11-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to investigate the bioequivalence of Mylan's fexofenadine 180
mg tablets to Aventis' Allegra® 180 mg tablets following a single, oral 180 mg (1 x 180 mg)
dose administered under fed conditions.